ventoline 5 mg/ ml
glaxosmithkline as - salbutamolsulfat - inhalasjonsvæske til nebulisator, oppløsning - 5 mg/ ml
ventoline 0.1 mg/ dose
glaxosmithkline as - salbutamolsulfat - inhalasjonsaerosol, suspensjon - 0.1 mg/ dose
voltarol 25 mg
glaxosmithkline consumer aps - diklofenakkalium - kapsel, myk - 25 mg
voltarol 12.5 mg
glaxosmithkline consumer healthcare a/s (1) - diklofenakkalium - kapsel, myk - 12.5 mg
duodart 0.5 mg / 0.4 mg
glaxosmithkline as - dutasterid / tamsulosinhydroklorid - kapsel, hard - 0.5 mg / 0.4 mg
zyvoxid 600 mg
pfizer as - linezolid - tablett, filmdrasjert - 600 mg
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiske midler - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
zeffix
glaxosmithkline (ireland) limited - lamivudin - hepatitt b, kronisk - antivirale midler til systemisk bruk - zeffix is indicated for the treatment of chronic hepatitis b in adults with: , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active liver inflammation and / or fibrosis. initiering av lamivudin behandling bør vurderes ved bruk av en alternativ antiviralt middel med en høyere genetisk barriere er ikke tilgjengelig eller hensiktsmessig;, dekompensert leversykdom i kombinasjon med en annen agent uten kryss-resistens mot lamivudin.
glucosamin pharma nord 400 mg
pharma nord aps produktion - glukosaminsulfatkaliumklorid - kapsel, hard - 400 mg
incruse ellipta (previously incruse)
glaxosmithkline (ireland) limited - umeclidiniumbromid - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - indikeres som en vedlikeholdsbronkodilatorbehandling for å lindre symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kol).